Press Releases

Biotium Expands Selection of Novel Nuclear Stains for Enhanced Multiplexing Flexibility for Microscopy and Flow Cytometry Applications

Biotium has announced the expansion of its NucSpot® Nuclear Stains lineup, offering unprecedented specificity and flexibility for nuclear counterstaining.

Horizon CME Announces First Annual Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer)

Horizon CME has announced its sponsorship of the first annual summit for the multidisciplinary conference, Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer).

ENPICOM partners with Erasmus University Medical Center in groundbreaking effort to discover nanobodies against cancer

ENPICOM has announced a collaboration with Erasmus Medical Center. This partnership aims to identify and develop nanobodies against cancer by utilizing ENPICOM’s immune repertoire data analysis services and software solutions.

Novel Drug Delivery System Unveiled: CD Formulation Launches Oral Thin Films Technology

Paradigm Clinical Research Expands Into Boise, Idaho, Advancing the Company’s Portfolio of Therapeutic Area Expertise

CD BioSciences Announces Its Self-Developed Alginate Products, Looking to Fulfill Research Needs

CD BioSciences is pleased to announce the launch of their latest self-developed alginate products, looking to fulfill scientific research demands.

Alfa Chemistry Unveils Expanded Assortment of Derivatization Reagents for Use in Gas Chromatography (GC)

Amerigo Scientific Launches DOPC Nanodiscs as An Invaluable Tool for Handling Membrane Proteins

Clinical Trial Media Tops Over 1,000 Participants Enrolled in Alzheimer’s Disease Studies Across 400 Trial Sites

Clinical Trial Media is Responsible for Identifying, Recruiting and Contributing Over 45% of Participants Across Multiple High-Demand Trials

REMEDI8 Highlights Mobile Containment Unit for Infection Control in the Healthcare Industry

HEPA-10X mitigates the spread of infection in high-risk healthcare environments

Catawba Research Collaborates With Bingli Inc. to Make Patient Pre-Screening Easier for Participants and Sites

PrecisionLife and Metrodora Institute Partner to Accelerate the Diagnosis and Treatment of Long COVID, ME/CFS, and other Chronic Conditions

PrecisionLife and Metrodora Institute are co-investing in a first-of-its-kind partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic diseases including Long COVID, ME/CFS, ALS, Sjögren's syndrome, and many more.

uMed helps Queen Mary University of London and University College London move closer to understanding Parkinson’s risk factors as first-of-its-kind study exceeds 10,000 participant milestone

uMed, the health and research technology company has played a crucial role in expanding the participant base of PREDICT-PD - a joint studybetween Queen Mary University of London and University College London (UCL), and funded by Parkinson’s UK investigating the onset and early stages of Parkinson's disease

Biofourmis Secures Four New Agreements with Top-20 Pharma on Strength of Platform for Digital Clinical Trials and Digital Biomarkers

Biofourmis Secures Four New Agreements with Top-20 Pharma on Strength of Platform for Digital Clinical Trials and Digital Biomarkers

Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies

Abzena launches LabZient™, an analytical platform accelerating antibody development timelines by combining predictive in-silico evaluation with laboratory methods. LabZient™ streamlines assessment, reduces costs, and enables early measurement of critical quality attributes. Fit-for-purpose across various antibody types, including mAbs and ADCs, LabZient™ enhances efficiency in biopharma development.

AES Clean Technology enhances cleanroom construction capabilities through new senior appointment

Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing

About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics completed Bio Campus I with Plant 4, offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 180KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise. Samsung Biologics Media Contact Claire Kim, Head of Marketing Communications cair.kim@samsung.com About LegoChem Biosciences, Inc. LegoChem Biosciences (KOSDAQ: 141080) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry and ADC platform technology ConjuAll. Since its foundation in 2006, LCB has focused on researching and developing Antibody-Drug-Conjugates (ADCs), anticancer therapeutics, antibiotics, and anti-fibrotic based on proprietary platform technologies. For more information, visit LegoChem Biosciences, Inc. at https://www.legochembio.com/index.php?lang=e LegoChem Biosciences Media Contact Daeyoung Jeong, Team Leader of IR/BD jdy@legochembio.com

Alfa Chemistry Releases Carbomer Series Products for Cosmetics and Personal Care Products Manufacturing

CD Formulation Shows the Ability of Coated Microneedle Preparation Technology for Novel Drug Delivery

Alfa Chemistry Catalysts: Porphyrin Ligands, Phthalocyanine Ligands Are Newly Released for the Science Community